Request for the Technical Review of 14 Draft Immediately Dangerous to Life or Health (IDLH) Value Profiles, 24930-24931 [2015-10295]
Download as PDF
<![CDATA[
24930
Federal Register / Vol. 80, No. 84 / Friday, May 1, 2015 / Notices
You may submit comments,
identified by CDC–2015–0020 and
docket number NIOSH 156–A, by either
of the two following methods:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: National Institute for
Occupational Safety and Health, NIOSH
Docket Office, 1090 Tusculum Avenue,
MS C–34, Cincinnati, OH 45226.
Instructions: All information received
in response to this notice must include
the agency name and docket number
[CDC–2015–0020; NIOSH 156–A]. All
relevant comments received will be
posted without change to
www.regulations.gov, including any
personal information provided. All
electronic comments should be
formatted as Microsoft Word. For access
to the docket to read background
documents or comments received, go to
www.regulations.gov. All information
received in response to this notice will
also be available for public examination
and copying at the NIOSH Docket
Office, 1150 Tusculum Avenue, Room
155, Cincinnati, OH 45226.
FOR FURTHER INFORMATION CONTACT: G.
Scott Dotson, NIOSH, Robert A. Taft
Laboratories, MS C–32, 1090 Tusculum
Avenue, Cincinnati, OH 45226. (513)
533–8540 (not a toll free number).
SUPPLEMENTARY INFORMATION: The draft
documents are based on the process
outlined in the NIOSH Current
ADDRESSES:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket Number CDC–2015–0020; NIOSH
156–A]
Request for the Technical Review of 14
Draft Immediately Dangerous to Life or
Health (IDLH) Value Profiles
National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS).
ACTION: Request for information and
comment.
AGENCY:
The National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC) is
conducting a public review of the draft
immediately dangerous to life or health
(IDLH) values and support technical
documents, entitled IDLH Values
Profiles, for 14 chemicals. NIOSH is
requesting technical reviews of the draft
IDLH Value Profiles.
DATES: Electronic or written comments
on the 14 documents contained within
Group A must be received on or before
June 30, 2015.
SUMMARY:
Document No.
...........................
...........................
...........................
...........................
...........................
...........................
A–07
A–08
A–09
A–10
A–11
A–12
A–13
A–14
mstockstill on DSK4VPTVN1PROD with NOTICES
A–01
A–02
A–03
A–04
A–05
A–06
...........................
...........................
...........................
...........................
...........................
...........................
...........................
...........................
Chemical(s)
Acrylonitrile ......................................................................................................................................
Benzonitrile ......................................................................................................................................
Methyl isocyanate ...........................................................................................................................
HCFC–141B ....................................................................................................................................
Chloroacetyl chloride .......................................................................................................................
Chlorine pentafluoride .....................................................................................................................
Bromine pentafluoride .....................................................................................................................
Iron pentacarbonyl ..........................................................................................................................
1,3-Butadiene ..................................................................................................................................
Diketene ..........................................................................................................................................
Furan ...............................................................................................................................................
Hexafluoroacetone ..........................................................................................................................
n-Butyl acrylate ...............................................................................................................................
Peracetic acid ..................................................................................................................................
Butane .............................................................................................................................................
Each IDLH Value Profile provides a
detailed summary of the health hazards
of acute exposures to high airborne
concentrations and the rationale for the
proposed IDLH value with the
chemical(s) of interest.
In 2013, NIOSH published Current
Intelligence Bulletin (CIB) 66—
Derivation of Immediately Dangerous to
Life or Health (IDLH) Values [NIOSH
2014–100; https://www.cdc.gov/niosh/
docs/2014-100/pdfs/2014-100.pdf]. The
VerDate Sep<11>2014
Intelligence Bulletin 66—Derivation of
Immediately Dangerous to Life or Health
(IDLH) Values https://www.cdc.gov/
niosh/docs/2014-100/pdfs/2014100.pdf. To facilitate the review of these
documents, NIOSH requests that the
following questions be taken into
consideration:
1. Does this document clearly outline
the health hazards associated with acute
(or short-term) exposures to the
chemical? If not, what specific
information is missing from the
document?
2. Are the rationale and logic behind
the derivation of an IDLH value for a
specific chemical clearly explained? If
not, what specific information is needed
to clarify the basis of the IDLH value?
3. Are the conclusions supported by
the data?
4. Are the tables clear and
appropriate?
5. Is the document organized
appropriately? If not, what
improvements are needed?
6. Are you aware of any scientific data
reported in governmental publications,
databases, peer-reviewed journals, or
other sources that should be included
within this document?
NIOSH seeks comments on 14 draft
IDLH values and IDLH Value Profiles.
The draft IDLH Value Profiles were
developed to provide the scientific
rationale behind derivation of IDLH
values for the following chemicals:
18:14 Apr 30, 2015
Jkt 235001
draft documents available for public
review use the methodology in this
document. Since the establishment of
the IDLH values in the 1970s, NIOSH
has continued to review available
scientific data to improve the protocol
used to derive acute exposure
guidelines, in addition to the chemicalspecific IDLH values. The information
presented in this CIB represents the
most recent update of the scientific
rationale and the methodology (hereby
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
(CAS#
(CAS#
(CAS#
(CAS#
(CAS#
(CAS#
(CAS#
(CAS#
(CAS#
(CAS#
(CAS#
(CAS#
(CAS#
(CAS#
(CAS#
107–13–1)
100–47–0)
624–83–9)
1717–00–6)
79–04–9)
13637–63–3)
7789–30–2)
13463–40–6)
106–99–0)
674–82–8)
110–00–9)
684–16–2)
141–32–2)
79–21–0)
106–97–8).
referred to as the IDLH methodology)
used to derive IDLH values. The
primary objectives of this document are
to:
1. Provide a brief history of the
development of IDLH values
2. Update the scientific basis and risk
assessment methodology used to derive
IDLH values from quality data
3. Provide transparency behind the
rationale and derivation process for
IDLH values
E:\FR\FM\01MYN1.SGM
01MYN1
mstockstill on DSK4VPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 84 / Friday, May 1, 2015 / Notices
4. Demonstrate how scientifically
credible IDLH values can be derived
from available data resources
The IDLH methodology outlined in
this CIB reflects the modern principles
and understanding in the fields of risk
assessment, toxicology, and
occupational health and provides the
scientific rationale for the derivation of
IDLH values based on contemporary risk
assessment practices. According to this
protocol, IDLH values are based on
health effects considerations determined
through a critical assessment of the
toxicology and human health effects
data. This approach ensures that the
IDLH values reflect an airborne
concentration of a substance that
represents a high-risk situation that may
endanger workers’ lives or health.
Relevant airborne concentrations are
typically addressed through the
characterization of inhalation
exposures; however, airborne chemicals
can also contribute to toxicity through
other exposure routes, such as the skin
and eyes. In this document, airborne
concentrations are referred to as acute
inhalation limits or guidelines to adhere
to commonly used nomenclature.
The emphasis on health effects is
consistent with both the traditional use
of IDLH values as a component of the
respirator selection logic and the
growing applications of IDLH values in
Risk Management Plan (RMPs) for nonroutine work practices governing
operations in high-risk environments
(e.g., confined spaces) and the
development of Emergency
Preparedness Plans (EPPs). Incorporated
in the IDLH methodology are the
standing guidelines and procedures
used for the development of
community-based acute exposure limits
called Acute Exposure Guideline Levels
(AEGLs). The inclusion of the AEGL
methodology has helped ensure that the
health-based IDLH values derived with
use of the guidance provided in this
document are based on validated
scientific rationale.
The IDLH methodology is based on a
weight-of-evidence approach that
applies scientific judgment for critical
evaluation of the quality and
consistency of scientific data and in
extrapolation from the available data to
the IDLH value. The weight-of-evidence
approach refers to critical examination
of all available data from diverse lines
of evidence and the derivation of a
scientific interpretation on the basis of
the collective body of data, including its
relevance, quality, and reported results.
This is in contrast to a purely
hierarchical or strength-of-evidence
approach, which relies on rigid decision
criteria for selecting a critical adverse
VerDate Sep<11>2014
18:14 Apr 30, 2015
Jkt 235001
24931
effect, a point of departure (POD), or the
point on the dose–response curve from
which dose extrapolation is initiated
and for applying default uncertainty
factors (UFs) to derive the IDLH value.
Conceptually, the derivation process for
IDLH values is similar to that used in
other risk assessment applications,
including these steps:
1. Hazard characterization.
2. Identification of critical adverse
effects.
3. Identification of a POD.
4. Application of appropriate UFs,
based on the study and POD.
responses; and (e) Assess information
collection costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570 or
send an email to omb@cdc.gov. Written
comments and/or suggestions regarding
the items contained in this notice
should be directed to the Attention:
CDC Desk Officer, Office of Management
and Budget, Washington, DC 20503 or
by fax to (202) 395–5806. Written
comments should be received within 30
days of this notice.
Dated: April 24, 2015.
John Howard,
Director, National Institute for Occupational
Safety and Health, Centers for Disease Control
and Prevention.
Proposed Project
Public Health Associate Program
(PHAP) Alumni Assessment—New—
Office for State, Tribal, Local, and
Territorial Support (OSTLTS)—
(proposed), Centers for Disease Control
and Prevention (CDC).
[FR Doc. 2015–10295 Filed 4–30–15; 8:45 am]
BILLING CODE 4163–19–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–15–15IG]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) has submitted the
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995. The notice for
the proposed information collection is
published to obtain comments from the
public and affected agencies.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information are encouraged. Your
comments should address any of the
following: (a) Evaluate whether the
proposed collection of information is
necessary for the proper performance of
the functions of the agency, including
whether the information will have
practical utility; (b) Evaluate the
accuracy of the agencies estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected; (d) Minimize the burden of
the collection of information on those
who are to respond, including through
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
Background and Brief Description
The Centers for Disease Control and
Prevention (CDC) works to protect
America from health, safety and security
threats, both foreign and in the U.S.
CDC strives to fulfill this mission, in
part, through a competent and capable
public health workforce. One
mechanism to developing the public
health workforce is through training
programs like the Public Health
Associate Program (PHAP).
The mission of PHAP is to train and
provide experiential learning to early
career professionals who contribute to
the public health workforce. PHAP
targets recent graduates with bachelors
or masters degrees who are beginning a
career in public health. Each year, a new
cohort of up to 200 associates is
enrolled in the program. Associates are
CDC employees who complete two-year
assignments in a host site (i.e., a state,
tribal, local, or territorial health
department or non-profit organization).
Host sites design their associates’
assignments to meet their agency’s
unique needs while also providing onthe-job experience that prepares
associates for future careers in public
health. Associates also receive CDCbased training in core public health
concepts and topics to provide the
knowledge, skills, and abilities
necessary to succeed in their
assignments and provide a foundation
for a career in public health. PHAP
hosts an initial in-person orientation
and annual public health training at
CDC and offers long-distance learning
opportunities throughout the program. It
is the goal of PHAP that following
participation in the two-year program,
alumni will seek employment within
the public health system (i.e., federal,
E:\FR\FM\01MYN1.SGM
01MYN1
]]>Agencies
[Federal Register Volume 80, Number 84 (Friday, May 1, 2015)]
[Notices]
[Pages 24930-24931]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-10295]
[[Page 24930]]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket Number CDC-2015-0020; NIOSH 156-A]
Request for the Technical Review of 14 Draft Immediately
Dangerous to Life or Health (IDLH) Value Profiles
AGENCY: National Institute for Occupational Safety and Health (NIOSH)
of the Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Request for information and comment.
-----------------------------------------------------------------------
SUMMARY: The National Institute for Occupational Safety and Health
(NIOSH) of the Centers for Disease Control and Prevention (CDC) is
conducting a public review of the draft immediately dangerous to life
or health (IDLH) values and support technical documents, entitled IDLH
Values Profiles, for 14 chemicals. NIOSH is requesting technical
reviews of the draft IDLH Value Profiles.
DATES: Electronic or written comments on the 14 documents contained
within Group A must be received on or before June 30, 2015.
ADDRESSES: You may submit comments, identified by CDC-2015-0020 and
docket number NIOSH 156-A, by either of the two following methods:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: National Institute for Occupational Safety and
Health, NIOSH Docket Office, 1090 Tusculum Avenue, MS C-34, Cincinnati,
OH 45226.
Instructions: All information received in response to this notice
must include the agency name and docket number [CDC-2015-0020; NIOSH
156-A]. All relevant comments received will be posted without change to
www.regulations.gov, including any personal information provided. All
electronic comments should be formatted as Microsoft Word. For access
to the docket to read background documents or comments received, go to
www.regulations.gov. All information received in response to this
notice will also be available for public examination and copying at the
NIOSH Docket Office, 1150 Tusculum Avenue, Room 155, Cincinnati, OH
45226.
FOR FURTHER INFORMATION CONTACT: G. Scott Dotson, NIOSH, Robert A. Taft
Laboratories, MS C-32, 1090 Tusculum Avenue, Cincinnati, OH 45226.
(513) 533-8540 (not a toll free number).
SUPPLEMENTARY INFORMATION: The draft documents are based on the process
outlined in the NIOSH Current Intelligence Bulletin 66--Derivation of
Immediately Dangerous to Life or Health (IDLH) Values https://www.cdc.gov/niosh/docs/2014-100/pdfs/2014-100.pdf. To facilitate the
review of these documents, NIOSH requests that the following questions
be taken into consideration:
1. Does this document clearly outline the health hazards associated
with acute (or short-term) exposures to the chemical? If not, what
specific information is missing from the document?
2. Are the rationale and logic behind the derivation of an IDLH
value for a specific chemical clearly explained? If not, what specific
information is needed to clarify the basis of the IDLH value?
3. Are the conclusions supported by the data?
4. Are the tables clear and appropriate?
5. Is the document organized appropriately? If not, what
improvements are needed?
6. Are you aware of any scientific data reported in governmental
publications, databases, peer-reviewed journals, or other sources that
should be included within this document?
NIOSH seeks comments on 14 draft IDLH values and IDLH Value
Profiles. The draft IDLH Value Profiles were developed to provide the
scientific rationale behind derivation of IDLH values for the following
chemicals:
----------------------------------------------------------------------------------------------------------------
Document No. Chemical(s)
----------------------------------------------------------------------------------------------------------------
A-01.................................. Acrylonitrile................... (CAS# 107-13-1)
A-02.................................. Benzonitrile.................... (CAS# 100-47-0)
A-03.................................. Methyl isocyanate............... (CAS# 624-83-9)
A-04.................................. HCFC-141B....................... (CAS# 1717-00-6)
A-05.................................. Chloroacetyl chloride........... (CAS# 79-04-9)
A-06.................................. Chlorine pentafluoride.......... (CAS# 13637-63-3)
Bromine pentafluoride........... (CAS# 7789-30-2)
A-07.................................. Iron pentacarbonyl.............. (CAS# 13463-40-6)
A-08.................................. 1,3-Butadiene................... (CAS# 106-99-0)
A-09.................................. Diketene........................ (CAS# 674-82-8)
A-10.................................. Furan........................... (CAS# 110-00-9)
A-11.................................. Hexafluoroacetone............... (CAS# 684-16-2)
A-12.................................. n-Butyl acrylate................ (CAS# 141-32-2)
A-13.................................. Peracetic acid.................. (CAS# 79-21-0)
A-14.................................. Butane.......................... (CAS# 106-97-8).
----------------------------------------------------------------------------------------------------------------
Each IDLH Value Profile provides a detailed summary of the health
hazards of acute exposures to high airborne concentrations and the
rationale for the proposed IDLH value with the chemical(s) of interest.
In 2013, NIOSH published Current Intelligence Bulletin (CIB) 66--
Derivation of Immediately Dangerous to Life or Health (IDLH) Values
[NIOSH 2014-100; https://www.cdc.gov/niosh/docs/2014-100/pdfs/2014-100.pdf]. The draft documents available for public review use the
methodology in this document. Since the establishment of the IDLH
values in the 1970s, NIOSH has continued to review available scientific
data to improve the protocol used to derive acute exposure guidelines,
in addition to the chemical-specific IDLH values. The information
presented in this CIB represents the most recent update of the
scientific rationale and the methodology (hereby referred to as the
IDLH methodology) used to derive IDLH values. The primary objectives of
this document are to:
1. Provide a brief history of the development of IDLH values
2. Update the scientific basis and risk assessment methodology used
to derive IDLH values from quality data
3. Provide transparency behind the rationale and derivation process
for IDLH values
[[Page 24931]]
4. Demonstrate how scientifically credible IDLH values can be
derived from available data resources
The IDLH methodology outlined in this CIB reflects the modern
principles and understanding in the fields of risk assessment,
toxicology, and occupational health and provides the scientific
rationale for the derivation of IDLH values based on contemporary risk
assessment practices. According to this protocol, IDLH values are based
on health effects considerations determined through a critical
assessment of the toxicology and human health effects data. This
approach ensures that the IDLH values reflect an airborne concentration
of a substance that represents a high-risk situation that may endanger
workers' lives or health. Relevant airborne concentrations are
typically addressed through the characterization of inhalation
exposures; however, airborne chemicals can also contribute to toxicity
through other exposure routes, such as the skin and eyes. In this
document, airborne concentrations are referred to as acute inhalation
limits or guidelines to adhere to commonly used nomenclature.
The emphasis on health effects is consistent with both the
traditional use of IDLH values as a component of the respirator
selection logic and the growing applications of IDLH values in Risk
Management Plan (RMPs) for non-routine work practices governing
operations in high-risk environments (e.g., confined spaces) and the
development of Emergency Preparedness Plans (EPPs). Incorporated in the
IDLH methodology are the standing guidelines and procedures used for
the development of community-based acute exposure limits called Acute
Exposure Guideline Levels (AEGLs). The inclusion of the AEGL
methodology has helped ensure that the health-based IDLH values derived
with use of the guidance provided in this document are based on
validated scientific rationale.
The IDLH methodology is based on a weight-of-evidence approach that
applies scientific judgment for critical evaluation of the quality and
consistency of scientific data and in extrapolation from the available
data to the IDLH value. The weight-of-evidence approach refers to
critical examination of all available data from diverse lines of
evidence and the derivation of a scientific interpretation on the basis
of the collective body of data, including its relevance, quality, and
reported results. This is in contrast to a purely hierarchical or
strength-of-evidence approach, which relies on rigid decision criteria
for selecting a critical adverse effect, a point of departure (POD), or
the point on the dose-response curve from which dose extrapolation is
initiated and for applying default uncertainty factors (UFs) to derive
the IDLH value. Conceptually, the derivation process for IDLH values is
similar to that used in other risk assessment applications, including
these steps:
1. Hazard characterization.
2. Identification of critical adverse effects.
3. Identification of a POD.
4. Application of appropriate UFs, based on the study and POD.
Dated: April 24, 2015.
John Howard,
Director, National Institute for Occupational Safety and Health,
Centers for Disease Control and Prevention.
[FR Doc. 2015-10295 Filed 4-30-15; 8:45 am]
BILLING CODE 4163-19-P
